Lexicon Pharmaceuticals (LXRX) Revenue (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Revenue of $21.1 million for Q1 2026, up 1572.11% year-over-year from $1.3 million in Q1 2025, and up 284.16% quarter-over-quarter from $5.5 million in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Revenue (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Revenue for 16 consecutive years, with $21.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 1572.11% year-over-year to $21.1 million; the TTM figure through Mar 2026 stood at $69.6 million (up 123.12% YoY), while the FY2025 annual figure was $49.8 million, up 60.24% from the prior year.
- Revenue rose to $21.1 million in Q1 2026 per LXRX's latest filing, from $5.5 million in the prior quarter.
- Across five years, Revenue topped out at $28.9 million in Q2 2025 and bottomed at $35000.0 in Q2 2022.
- Historically, Revenue has averaged $7.9 million across 5 years, with a median of $1.6 million in 2024.
- Annual changes were most pronounced in 2024 — Revenue jumped 3366.58% — and 2025, when it tumbled 79.31%.
- Lexicon Pharmaceuticals' Revenue stood at $35000.0 in 2022, then soared by 2088.57% to $766000.0 in 2023, then surged by 3366.58% to $26.6 million in 2024, then sank by 79.31% to $5.5 million in 2025, then jumped by 284.16% to $21.1 million in 2026.
- Business Quant data shows LXRX's Revenue at $21.1 million in Q1 2026, $5.5 million in Q4 2025, and $14.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 145.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 1.71 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 674.14 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | 692,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 692,000.00 |
| Mar 31, 2026 | 21.10 Mn |
| Dec 31, 2025 | 5.49 Mn |
| Sep 30, 2025 | 14.18 Mn |
| Jun 30, 2025 | 28.87 Mn |
| Mar 31, 2025 | 1.26 Mn |
| Dec 31, 2024 | 26.55 Mn |
| Sep 30, 2024 | 1.75 Mn |
| Jun 30, 2024 | 1.65 Mn |
| Mar 31, 2024 | 1.13 Mn |
| Dec 31, 2023 | 702,000.00 |
| Sep 30, 2023 | 162,000.00 |
| Jun 30, 2023 | 317,000.00 |
| Mar 31, 2023 | 24,000.00 |
| Dec 31, 2022 | 28,000.00 |
| Sep 30, 2022 | 39,000.00 |
| Jun 30, 2022 | 35,000.00 |
| Dec 31, 2021 | 14,000.00 |
| Sep 30, 2021 | 23,000.00 |
| Jun 30, 2021 | 234,000.00 |